Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Increasing provider awareness of Lp(a) testing for patients at risk for cardiovascular disease: A comparative study.
Am J Prev Cardiol
March 2025
St. Elizabeth Healthcare, 20 Medical Village Drive, Suite 103, Edgewood, KY 41017, USA.
Background: Lipoprotein(a) [Lp(a)] is a low-density lipoprotein variant with atherogenic, thrombogenic, and pro-inflammatory properties that may have numerous pathologic effects, including dyslipidemia. Screening for Lp(a) is clinically significant, due to its causal role in atherosclerotic cardiovascular disease (ASCVD). Among clinicians, however, there remains a general lack of both clinical awareness of Lp(a) and adequate tools to track Lp(a) testing in patients.
View Article and Find Full Text PDFAn up-to-date review of emerging biologic therapies for hypercholesterolemia.
Expert Opin Biol Ther
January 2025
Faculty of Medicine, Macau University of Science & Technology, Macau, China.
Introduction: Hypercholesterolemia and other lipid disorders are major causes of atherosclerotic cardiovascular disease (ASCVD). Statins have been the mainstay of lipid-lowering therapy for many years, but they may not be adequate to achieve the target low-density lipoprotein (LDL) cholesterol levels and there are other residual lipid risk factors.
Areas Covered: This article reviews the biologic therapies in development for hypercholesterolemia identified by a PubMed search.
Apolipoprotein B Modifies the Association between Lipoprotein(a) and ASCVD Risk.
Am Heart J
December 2024
Cardiology Department, First Affiliated Hospital of Sun Yat-Sen University. Electronic address:
Background: Elevated lipoprotein(a) (Lp[a]) and apolipoprotein B (apoB) are individually associated with the risk of atherosclerotic cardiovascular disease (ASCVD). Moreover, previous basic research has implicated the potential interaction between apoB and Lp(a) in the atherogenic process. We aimed to determine whether apoB levels significantly modulate ASCVD risk associated with Lp(a) in a large community-based population without baseline cardiovascular disease.
View Article and Find Full Text PDFTraditional Risk Factors, Optimal Cardiovascular Health, and Elevated Lipoprotein(a).
Eur J Prev Cardiol
November 2024
Division of Cardiovascular Medicine, Sulpizio Cardiovascular Center, University of California San Diego, La Jolla, CA.
Aims: To assess the association of traditional risk factor burden and Life's Simple 7 (LS7) score with incident atherosclerotic cardiovascular disease (ASCVD) across Lp(a) levels.
Methods: There were 6,676 participants without clinical ASCVD from the Multi-Ethnic Study of Atherosclerosis who underwent Lp(a) testing and were followed for incident ASCVD events (coronary heart disease and stroke). Low, intermediate, and elevated Lp(a) were defined as <30, 30-49, and >50 mg/dL, respectively.
Zerlasiran-A Small-Interfering RNA Targeting Lipoprotein(a): A Phase 2 Randomized Clinical Trial.
JAMA
December 2024
Silence Therapeutics, London, United Kingdom.
Importance: Elevated lipoprotein(a) increases the risk of atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis.
Objective: To evaluate the effects of zerlasiran, a small-interfering RNA targeting hepatic synthesis of apolipoprotein(a), on lipoprotein(a) serum concentration.
Design, Setting, And Participants: A multicenter trial in patients with stable ASCVD with serum lipoprotein(a) concentrations greater than or equal to 125 nmol/L at 26 sites in Europe and South Africa between January 3, 2023, and April 27, 2023, with last follow-up on July 1, 2024.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!